shutterstock_1873015870_alpha_tauri_3d_graphics
Alpha Tauri 3D Graphics / Shutterstock.com
23 August 2022FeaturesBiotechIne Vanderleyden

Microbial consortia and IP in Europe

Our body hosts trillions of microorganisms that live symbiotically on and within the human body. This ‘microbiome’ is essential to our health and microbial imbalance or dysbiosis increases the susceptibility to many diseases, including inflammatory bowel disease (IBD), liver disease, atherosclerosis, and other severe pathologies. Given its central role in health and disease, the microbiome has become a prominent therapeutic target.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.
Biotech
20 July 2026   The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.
Biotech
16 July 2026   A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.